Control of an outbreak of human parainfluenza virus 3 in hematopoietic stem cell transplant recipients
- PMID: 19781656
- PMCID: PMC7172256
- DOI: 10.1016/j.bbmt.2009.09.014
Control of an outbreak of human parainfluenza virus 3 in hematopoietic stem cell transplant recipients
Abstract
Human parainfluenza virus 3 (HPIV3) infection can cause significant morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). There are no standard guidelines for the prevention and control of HPIV3 in the outpatient setting. After 2 HSCT inpatients diagnosed with HPIV3 were noted to have had multiple recent HSCT outpatient clinic (OPC) visits, an investigation of policy and procedures in the HSCT OPC was undertaken, and active surveillance for respiratory viral illness was instituted in the at-risk HSCT population. Between July 19 and August 30, 2005, 13 patients were diagnosed with HPIV3 infection. Morbidity in affected patients was significant, and mortality was high (38.5%) and not affected by antiviral therapy. Molecular typing identified several genetically distinct groups of the hemagglutinin-neuraminidase gene of the 11 available isolates. Based on sequence relatedness among the isolates and the demographic and exposure history of the patients, in many of these cases HPIV3 infection likely was acquired in the HSCT OPC. The major infection control interventions were introduced between August 20 and August 24. An epidemic curve revealed that HPIV3 infection frequency peaked between August 17 and August 26, with no cases identified after August 30. Prompt attention and focus on infection control interventions were associated with a rapid decrease in the number of incident cases. Policies and procedures regarding patients with respiratory viral illnesses in HSCT OPC populations should be formulated and universally reinforced with HSCT clinic staff to prevent the spread of these infections.
Copyright 2010 Elsevier Inc. All rights reserved.
Figures


Similar articles
-
Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population.J Infect Dis. 2001 Nov 1;184(9):1093-7. doi: 10.1086/322041. Epub 2001 Oct 12. J Infect Dis. 2001. PMID: 11598830
-
An outbreak of human parainfluenza virus 3 infection in an outpatient hematopoietic stem cell transplantation clinic.Am J Infect Control. 2012 Sep;40(7):601-5. doi: 10.1016/j.ajic.2011.11.011. Epub 2012 Mar 8. Am J Infect Control. 2012. PMID: 22405748
-
Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis.Biol Blood Marrow Transplant. 2004 Jan;10(1):58-64. doi: 10.1016/j.bbmt.2003.09.010. Biol Blood Marrow Transplant. 2004. PMID: 14752780
-
New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase.Antiviral Res. 2019 Jul;167:89-97. doi: 10.1016/j.antiviral.2019.04.001. Epub 2019 Apr 3. Antiviral Res. 2019. PMID: 30951732 Review.
-
Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.Clin Infect Dis. 2014 Nov 15;59 Suppl 5(Suppl 5):S344-51. doi: 10.1093/cid/ciu623. Clin Infect Dis. 2014. PMID: 25352629 Free PMC article. Review.
Cited by
-
Risk Factors for Parainfluenza Virus Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant. 2019 Jan;25(1):163-171. doi: 10.1016/j.bbmt.2018.08.021. Epub 2018 Aug 25. Biol Blood Marrow Transplant. 2019. PMID: 30149147 Free PMC article. Clinical Trial.
-
Perspective: emerging challenges in the treatment of influenza and parainfluenza in transplant patients.Adv Virol. 2011;2011:910930. doi: 10.1155/2011/910930. Epub 2011 Jul 7. Adv Virol. 2011. PMID: 22312357 Free PMC article.
-
Receptor-mediated cell entry of paramyxoviruses: Mechanisms, and consequences for tropism and pathogenesis.J Biol Chem. 2020 Feb 28;295(9):2771-2786. doi: 10.1074/jbc.REV119.009961. Epub 2020 Jan 16. J Biol Chem. 2020. PMID: 31949044 Free PMC article. Review.
-
Viral Entry Properties Required for Fitness in Humans Are Lost through Rapid Genomic Change during Viral Isolation.mBio. 2018 Jul 3;9(4):e00898-18. doi: 10.1128/mBio.00898-18. mBio. 2018. PMID: 29970463 Free PMC article.
-
Parainfluenza virus infections in patients with hematological malignancies or stem cell transplantation: Analysis of clinical characteristics, nosocomial transmission and viral shedding.PLoS One. 2022 Jul 29;17(7):e0271756. doi: 10.1371/journal.pone.0271756. eCollection 2022. PLoS One. 2022. PMID: 35905071 Free PMC article.
References
-
- Wendt C.H., Weisdorf D.J., Jordan M.C. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med. 1992;326:921–926. - PubMed
-
- Nichols G.W., Corey L., Gooley T. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood. 2001;98:573–578. - PubMed
-
- Lewis V.A., Champlin R., Englund J. Respiratory diseases due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis. 1996;23:1033–1037. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical